


Stabilis



Cytarabine



Handelsmarke

Alexan	Ägypten, Iran, Kolumbien, Luxemburg, Niederlande, Österreich, Saudi-Arabien, Tunesien, Türkei, Ungarn, Vereinigte Arabische Emirate
Ara Cell	Deutschland, Portugal
Arabine	Dänemark, Finnland, Island, Schweden
Aracytin	Ägypten, Brasilien, Chile, Griechenland, Italien, Kolumbien
Aracytine	Frankreich, Kolumbien, Marokko
Cancyt	Indien
Citarabina	Argentinien, Chile, Ecuador, Italien, Kolumbien, Mexiko, Spanien
Citos	Brasilien
Cykup	Mexiko
Cylocide	Japan
Cytaban	Kolumbien
Cytaloxan	Portugal
Cytarabine	Ägypten, Australien, Belgien, Finnland, Großbritannien, Irland, Kanada, Malaysia, Neuseeland, Vereinigte Arabische Emirate, Vereinigte Staaten von Amerika
Cytarax	Brasilien, Mexiko
Cyterobal	Mexiko
Cytonal	Türkei
Cytosafe	Großbritannien
Cytosar	Belgien, Dänemark, Iran, Kanada, Luxemburg, Malaysia, Mexiko, Niederlande, Österreich, Polen, Portugal, Saudi-Arabien, Schweiz, Ungarn, Venezuela, Vereinigte Arabische Emirate
Ifarab	Mexiko
Laracit	Chile, Kolumbien, Mexiko
Medsara	Mexiko
Novutrax	Kolumbien, Mexiko
Oncorab	Venezuela
Tabine	Ecuador



Stabilität der Lösung

		0,1 mg/ml	20-25°C		28			2255
		0,1 & 20 mg/ml	2-8°C		28			2255
		0,144 mg/ml	23°C		72			1501
		0,144 mg/ml	4°C		72			1501
		1 mg/ml	2-8°C		28			4455
		1 mg/ml	25°C		14			4455
		10 mg/ml	2-8°C		28			4455
		10 mg/ml	25°C		5			4455
		20 mg/ml	20-25°C		28			2255
		5 mg/ml	2-8°C		28			4455
		5 mg/ml	25°C		7			739
		5 mg/ml	25°C		8			4455
		0,1 mg/ml	20-25°C		14			2255
		0,1 & 20 mg/ml	2-8°C		28			2255
		0,144 mg/ml	23°C		72			1501
		0,144 mg/ml	4°C		72			1501
		20 mg/ml	20-25°C		28			2255
	RL	5 mg/ml	25°C		7			739
	E B	3 mg/ml	23°C		48			31
	E B	3 mg/ml	4°C		48			31
	E B	5 mg/ml	25°C		7			739
		0,1 mg/ml	20-25°C		28			2255
		0,1 & 20 mg/ml	2-8°C		28			2255
		0,144 mg/ml	23°C		72			1501
		0,144 mg/ml	4°C		72			1501
		20 mg/ml	20-25°C		28			2255
		0,1 mg/ml	20-25°C		14			2255
		0,1 & 20 mg/ml	2-8°C		28			2255
		0,144 mg/ml	23°C		72			1501
		0,144 mg/ml	4°C		72			1501

		20 mg/ml	20-25°C		28			2255
		0,1 mg/ml	20-25°C		28			2255
		0,1 & 20 mg/ml	2-8°C		28			2255
		0,144 mg/ml	21°C-22°C		72			1520
		0,144 mg/ml	23°C		72			1501
		0,144 mg/ml	4°C		72			1501
		0,144 mg/ml	4°C		72			1520
		20 mg/ml	20-25°C		28			2255
		0,1 mg/ml	20-25°C		14			2255
		0,1 & 20 mg/ml	2-8°C		28			2255
		0,144 mg/ml	21°C-22°C		72			1520
		0,144 mg/ml	23°C		72			1501
		0,144 mg/ml	4°C		72			1501
		0,144 mg/ml	4°C		72			1520
		20 mg/ml	20-25°C		28			2255
		0,157 mg/ml	25°C		48			152
		0,157 mg/ml	4°C		48			152
		1,25 & 25 mg/ml	22°C		28			142
		1,25 & 25 mg/ml	25°C		28			844
		1,25 & 25 mg/ml	35°C		7			142
		1,25 & 25 mg/ml	35°C		14			844
		1,25 & 25 mg/ml	4°C		28			142
		1,25 & 25 mg/ml	4°C		28			844
		1,25 & 25 mg/ml	22°C		28			142
		1,25 & 25 mg/ml	25°C		28			844
		1,25 & 25 mg/ml	35°C		7			142
		1,25 & 25 mg/ml	35°C		14			844
		1,25 & 25 mg/ml	4°C		28			142
		1,25 & 25 mg/ml	4°C		28			844
		20 & 50 mg/ml	21°C		30			1229
		20 & 50 mg/ml	6°C-9°C		30			1229
		0,1 mg/ml	20-25°C		28			2255
		0,1 & 20 mg/ml	2-8°C		28			2255

		1 mg/ml	2-8°C		28			4455
		1 mg/ml	25°C		14			4455
		10 mg/ml	2-8°C		28			4455
		10 mg/ml	25°C		5			4455
		20 mg/ml	20-25°C		28			2255
		5 mg/ml	2-8°C		28			4455
		5 mg/ml	25°C		8			4455
		0,1 mg/ml	20-25°C		14			2255
		0,1 & 20 mg/ml	2-8°C		28			2255
		20 mg/ml	20-25°C		28			2255
	E B	3 mg/ml	23°C	?	48			31
	E B	3 mg/ml	4°C		48			31
	Ø	20 & 50 mg/ml	-10°C		14			850
	Ø	20 & 50 mg/ml	22°C	?	14			850
	Ø	20 & 50 mg/ml	8°C		14			850



Gemengestabilität

								
		1 mg/ml	20°C-23°C		Granisetron hydrochloride : 0,5 mg/ml	4		57
		0,2 & 1 mg/ml	22°C		Sodium bicarbonate : 50 mg/ml	7		850
		0,2 & 1 mg/ml	8°C		Sodium bicarbonate : 50 mg/ml	7		850
	E B	0,442 mg/ml	23°C		Methotrexate sodium : 0,0279 mg/ml	48		1661
	E B	0,484 mg/ml	23°C		Methotrexate sodium : 0,0314 mg/ml Hydrocortisone sodium succinate : 0,478 mg/ml	48		1661
	E B	0,477 mg/ml	23°C		Methotrexate sodium : 0,0581 mg/ml Hydrocortisone sodium succinate : 0,467 mg/ml	48		1661
	E B	0,433 mg/ml	23°C		Methotrexate sodium : 0,0542 mg/ml	48		1661
	E B	0,479 mg/ml	23°C		Methotrexate sodium : 0,0721 mg/ml Hydrocortisone sodium succinate : 0,489 mg/ml	48		1661
	E B	0,431 mg/ml	23°C		Methotrexate sodium : 0,0649 mg/ml	48		1661
	E B	0,484 mg/ml	4°C		Methotrexate sodium : 0,0314 mg/ml Hydrocortisone sodium succinate : 0,478 mg/ml	48		1661
	E B	0,442 mg/ml	4°C		Methotrexate sodium : 0,0279 mg/ml	48		1661
	E B	0,477 mg/ml	4°C		Methotrexate sodium : 0,0581 mg/ml Hydrocortisone sodium succinate : 0,467 mg/ml	48		1661

	EI B	0,433 mg/ml	4°C	?	Methotrexate sodium : 0,0542 mg/ml	48	✓	1661
	EI B	0,479 mg/ml	4°C	?	Methotrexate sodium : 0,0721 mg/ml Hydrocortisone sodium succinate : 0,489 mg/ml	48	✓	1661
	EI B	0,431 mg/ml	4°C	?	Methotrexate sodium : 0,0649 mg/ml	48	✓	1661
		0,2 & 40 mg/ml	21°C-23°C		Ondansetron hydrochloride : 0,03 & 0,3 mg/ml	48	✓	184
		0,2 & 1 mg/ml	22°C	?	Sodium bicarbonate : 50 mg/ml	7	⬤	850
		0,2 & 1 mg/ml	8°C		Sodium bicarbonate : 50 mg/ml	7	⬤	850
		0,26 mg/ml	20°C		Daunorubicin hydrochloride : 0,03 mg/ml Etoposide : 0,4 mg/ml	72	✓	643
		0,157 mg/ml	25°C		Etoposide : 0,157 mg/ml Daunorubicin hydrochloride : 0,0157 mg/ml	48	✓	152
		0,157 mg/ml	4°C		Etoposide : 0,157 mg/ml Daunorubicin hydrochloride : 0,0157 mg/ml	48	✓	152
		4,1 mg/ml	25°C	?	Hydrocortisone sodium succinate : 2 mg/ml Methotrexate sodium : 1 mg/ml	24	✓	1028
		4,1 mg/ml	25°C	?	Hydrocortisone sodium succinate : 2 mg/ml Methotrexate sodium : 1 mg/ml	24	✓	1028
	RL	4,1 mg/ml	25°C	?	Hydrocortisone sodium succinate : 2 mg/ml Methotrexate sodium : 1 mg/ml	24	✓	1028
	EI B	4,1 mg/ml	25°C	?	Hydrocortisone sodium succinate : 2 mg/ml Methotrexate sodium : 1 mg/ml	24	✓	1028
	Ø	3,85 mg/ml	5°C		Methylprednisolone sodium succinate : 0,51 mg/ml Methotrexate sodium : 1,54 mg/ml	12	✓	3275



Stabilitätsbeeinflussende Faktoren

				2255
				301
	25°C			4455



Kompatibilitäten

	Cytarabine : 50 mg/ml Amifostine : 10 mg/ml		3
	Cytarabine	RL	739
	Cytarabine : 50 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
	Cytarabine : 50 mg/ml Amsacrine : 1 mg/ml		253
	Cytarabine : 50 mg/ml Anidulafungin : 0.5 mg/ml		1982
	Cytarabine : 50 mg/ml Aztreonam : 40 mg/ml		99

		Cytarabine		3580
		Cytarabine : 50 mg/ml Allopurinol sodium : 3 mg/ml		307
		Cytarabine : 50 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Cytarabine : 0.8 mg/ml Cefalotin sodium : 1 mg/ml		431
		Cytarabine Cefalotin sodium		3580
		Cytarabine : 50 mg/ml Cladribine : 0.015 mg/ml		1496
		Cytarabine Gentamicin sulfate		3580
		Cytarabine : 50 mg/ml		301
		Cytarabine : 50 mg/ml Cladribine : 0.5 mg/ml		1496
		Cytarabine : 50 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Cytarabine : 50 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Cytarabine : 50 mg/ml Filgrastim : 30 µg/ml		244
		Cytarabine : 50 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Cytarabine Fluorouracil		3474
		Cytarabine Fluorouracil		3580
		Cytarabine : 0.4 mg/ml Fluorouracil : 0.25 mg/ml		431
		Cytarabine : 50 mg/ml Gallium nitrate : 1 mg/ml		91
		Cytarabine : 50 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Cytarabine : 16 mg/ml Gentamicin sulfate : 15 mg/ml		132
		Cytarabine : 2 mg/ml Granisetron hydrochloride : 1 mg/ml		57
		Cytarabine Heparin sodium		3540
		Cytarabine Heparin sodium		3580
		Cytarabine : 16 mg/ml Hydrocortisone sodium succinate : 125 mg/ml		132
		Cytarabine Hydrocortisone sodium succinate		3580
		Cytarabine Insulin		3580
		Cytarabine : 50 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Cytarabine : 50 mg/ml Linezolid : 2 mg/ml		1925

		Cytarabine : 50 mg/ml Melfhalan : 0.1 mg/ml		169
		Cytarabine Methotrexate sodium	RL	978
		Cytarabine : 0.6 mg/ml Methotrexate sodium : 30 mg/ml		150
		Cytarabine : 0.4 mg/ml Methotrexate sodium : 0.2 mg/ml		431
		Cytarabine : 16 mg/ml Methylprednisolone sodium succinate : 5 mg/ml		132
		Cytarabine : 50 mg/ml		1415
		Cytarabine : 1 mg/ml Hydroxyzine dihydrochloride : 0.5 mg/ml		331
		Cytarabine : 6 mg/ml Idarubicin hydrochloride : 1 mg/ml		491
		Cytarabine Methotrexate sodium		3637
		Cytarabine Methotrexate sodium		3580
		Cytarabine : 16 mg/ml Methylprednisolone sodium succinate : 5 mg/ml		132
		Cytarabine : 0.6 mg/ml		150
		Cytarabine Methylprednisolone sodium succinate		3580
		Cytarabine Nafcillin sodium		3580
		Cytarabine : 0,2 mg/ml Ondansetron hydrochloride : 0,03 mg/ml		184
		Cytarabine : 50 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Cytarabine : 0,2 mg/ml Ondansetron hydrochloride : 0,3 mg/ml		184
		Cytarabine : 40 mg/ml Ondansetron hydrochloride : 0,3 mg/ml		184
		Cytarabine : 40 mg/ml Ondansetron hydrochloride : 0,03 mg/ml		184
		Cytarabine Oxacillin sodium		3580
		Cytarabine : 50 mg/ml Paclitaxel : 1.2 mg/ml		85
		Cytarabine : 50 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Cytarabine Penicillin G potassium		3580
		Cytarabine Penicillin G sodium		3585
		Cytarabine Penicillin G sodium		3580
		Cytarabine : 50 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Cytarabine : 50 mg/ml Propofol : 10 mg/ml		300

	Cytarabine : 50 mg/ml Sargramostim : 10 µg/ml		335
	Cytarabine : 0.6 mg/ml Sodium bicarbonate : 14 mg/ml		150
	Cytarabine : 50 mg/ml Teniposide : 0.1 mg/ml		905
	Cytarabine : 50 mg/ml Thiotepa : 1 mg/ml		249
	Cytarabine : 50 mg/ml Vinorelbine tartrate : 1 mg/ml		84
	Cytarabine		3580
	Cytarabine : 0.016 mg/ml Vincristine sulfate : 0.004 mg/ml		431



Applikationsart



Literaturverzeichnis

	Typ	Veröffentlichung
3	Zeitung	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
31	Zeitung	Zhang Y, Xu QA, Trissel LA, Gilbert DL. Physical and chemical stability of methotrexate sodium, cytarabine, and hydrocortisone sodium succinate in Elliott's B solution. Hosp Pharm 1996 ; 31: 965-970.
57	Zeitung	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
81	Zeitung	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Zeitung	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
85	Zeitung	Trissel LA, Bready BB. Turbidimetric assessment of the compatibility of taxol with selected other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 1716-1719.
91	Zeitung	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.

99	Zeitung	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
132	Zeitung	Najari Z, Rusho WJ. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. Am J Health-Syst Pharm 1997 ; 54: 181-184.
142	Zeitung	Rochard EB, Barthes DMC, Courtois PY. Stability of fluorouracil, cytarabine, or doxorubicin hydrochloride in ethylene vinylacetate portable infusion-pump reservoirs. Am J Hosp Pharm 1992 ; 49: 619-623.
150	Zeitung	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
152	Zeitung	Chevrier R, Sautou V, Pinon V, Demecop F, Chopineau J. Stability and compatibility of a mixture of the anti-cancer drugs etoposide, cytarabine and daunorubicine for infusion. Pharm Acta Helv 1995 ; 70: 141-148.
169	Zeitung	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
184	Zeitung	Stewart JT, Warren FW, King DT, Fox JL. Stability of ondansetron hydrochloride and five antineoplastic medications. Am J Health-Syst Pharm 1996 ; 53: 1297-1300.
244	Zeitung	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Zeitung	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Zeitung	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253	Zeitung	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
300	Zeitung	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Zeitung	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Zeitung	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
331	Zeitung	Marquardt ED. Visual compatibility of hydroxyzine hydrochloride with various antineoplastic agents. Am J Hosp Pharm 1988 ; 45: 2127.
334	Zeitung	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.

335	Zeitung	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
431	Zeitung	McRae MP, King JC. Compatibility of antineoplastic, antibiotic and corticosteroid drugs in intravenous admixtures. Am J Hosp Pharm 1975 ; 33: 1010-1013.
491	Zeitung	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	Zeitung	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
643	Zeitung	Seargeant LE, Kobrinsky NL, Sus CJ, Nazeravich DR. In vitro stability and compatibility of daunorubicin, cytarabine, and etoposide. Cancer Treat Rep 1987 ; 71: 1189-1192.
739	Zeitung	Cradock JC, Kleinmann LM, Rahman A. Evaluation of some pharmaceutical aspects of intrathecal methotrexate sodium, cytarabine and hydrocortisone sodium succinate. Am J Hosp Pharm 1978 ; 35: 402-406.
844	Zeitung	Rochard E, Chapelle G, Bouquet S, Barthes D, Courtois PH. Stability of fluorouracil and cytarabine in ethylvinylacetate containers. J Pharm Clin 1989 ; 9: 31-35.
850	Zeitung	Munson J, Kubiak EJ, Cohon MS. Cytosine arabinose stability in intravenous admixtures with sodium bicarbonate and in plastic syringes. Drug Intell Clin Pharm 1982 ; 16: 765-767.
905	Zeitung	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Zeitung	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
978	Zeitung	Dick DM, Woloschuk DMM. Methotrexate and cytarabine for intrathecal administration. Can J Hosp Pharm 1994 ; 47: 147.
1028	Zeitung	Cheung YW, Vishnuvajjala BR, Flora KP. Stability of cytarabine, methotrexate sodium, and hydrocortisone sodium succinate admixtures. Am J Hosp Pharm 1984 ; 41: 1802-1806.
1229	Zeitung	Weir PJ, Ireland DS. Chemical stability of cytarabine and vinblastine injections. Br J Pharm Pract 1990 ; 12: 53-54, 60.
1410	Zeitung	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Zeitung	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Zeitung	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.

1496	Zeitung	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1501	Zeitung	Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M. Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials. Int J Pharm 1999 ; 185: 113-121.
1520	Labor	Etude de stabilité des médicaments en Ecoflac® B Braun 2001
1625	Zeitung	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1661	Zeitung	Trissel LA, King KM, Zhang Y, Wood AM. Physical and chemical stability of methotrexate, cytarabine, and hydrocortisone in Elliott's B Solution for intrathecal use. J Oncol Pharm Practice 2002 ; 8: 27-32.
1925	Zeitung	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Zeitung	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Zeitung	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2247	Zeitung	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2255	Labor	Stability of Alexan "Ebewe" infusion solutions. Ebewe Pharma 2007
3275	Zeitung	D'Hondt M, Vangheluwe E, Van Dorpe S, Boonen J, Bauters T, Pelfrene B, Vandenbroucke J, Robays H, De Spiegeleer B Stability of extemporaneously prepared cytarabine, methotrexate sodium, and methylprednisolone sodium succinate Am J Health-Syst Pharm 2012 ; 69: 232-240.
3474	Labor	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3540	Labor	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3580	Labor	Cytarabine Accord - Résumé des caractéristiques du produit Accord Healthcare France 2016
3585	Labor	Benzylnicillin sodium - Summary of Product Characteristics Genus Pharmaceuticals 2008
3637	Labor	Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics Hameln Pharmaceuticals 2014
4455	Zeitung	Ben Ayed W, Drira C, Ali Soussi M, Ouesleti H, Hamdene B, Khrouf M, Safta F, Fradi I. Physical and chemical stability of cytarabine in polypropylene syringes. J Oncol Pharm Practice 2020 online first



Wörterbuch

	Antikrebsmittel		Injektion
	Handelsmarke		Stabilität der Lösung
	Behälter		Molekül
	Konzentration		Temperatur
	Konservierung		Dauer der Stabilität
	Biosimilar		widersprüchliche Daten
	Literaturverzeichnis		Glas
	0,9% Natriumchlorid		Mit oder ohne Licht
	Tag		Ohne Licht
	Stunde		Licht
	5% Glucose	RL	Ringer Lactat - Lösung
EI B	Elliott - Lösung	?	Nicht genau angegeben
	Polyvinylchlorid		Polyäthylen
	Polypropylen		Äthylenvinylacetat
	Spritze Polypropylen		Wasser für injektale präparate
	Kein		Gemengestabilität
	Lösungsmittel		Molekül
	0,45 NaCl 5% Glucose		Stabilitätbeeinflussende Faktoren
	Führt zu		Stabilitätsverringern
	Parenterale Ernährung (Lipid-frei)		Degradation
	Kompatibilitäten		kompatibel
	Niederschlag nach 4 Stunden		nicht kompatibel
	Nicht spezifizierte Inkompatibilität		Trübungsverlust
	0,9% NaCl + bakterostatsich		Chemische Instabilität
	Sofortiger Niederschlag		Niederschlag nach 1 Stunde
	Parenterale Ernährung (mit Lipiden)		NaHCO ₃
	Applikationsart		Intravenös
	Intravenöse Perfusion		Langzeitperfusion
	Intramuskulär		Subkutan
	Intrathekal		Literaturverzeichnis

